fluoromethylcholine

11/01/2016 - "11C-choline and 18F-choline are in wide clinical use outside the United States, and they have proven most beneficial for detection of recurrent prostate cancer. "
01/01/2020 - "18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies."
12/01/2023 - "This prospective, multicenter, open-label, randomized, crossover trial study was to evaluate the diagnostic performance of 18F-PSMA-1007 (PSMA) vs. 18F-Choline PET/CT (FCH) in prostate cancer (PCa) patients (pts) with biochemical recurrence (BCR). "
12/01/2023 - "Comparison of 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study."
10/01/2023 - "To study the feasibility of radiomic analysis of baseline [18F]fluoromethylcholine positron emission tomography/computed tomography (PET/CT) for the prediction of biochemical recurrence (BCR) in a cohort of intermediate and high-risk prostate cancer (PCa) patients. "

10/01/2022 - "18F-choline whole body PET/CT resulted negative for PC relapse, while segmental brain PET, co-registered with MRI, demonstrated increased tracer uptake corresponding to tumor boundaries. "
02/01/2022 - "Finally, this tumor displayed a high 18F-choline uptake, and no extracranial lesion was revealed with this tracer. "
12/01/2021 - "The interpretation of 18F-choline PET/CT in this cancer should be careful and discussed in a multidisciplinary team."
01/01/2021 - "In contrast, dynamic PET of [18F]fluoromethylcholine demonstrated no increase in tumor-to-muscle ratios due to an increase in both tumor and muscle over time. "
01/01/2020 - "The most promising model selected all high-risk disease on mpMRI (Likert 5 or PI-RADS 5) plus low- and intermediate-risk disease (Likert 4 or PI-RADS 3-4), with an elevated 18F-choline target-to-background ratio greater than 1.58 as positive for significant cancer. "

10/01/2016 - "For the detection of bone metastases, 11C- or 18F-choline PET/CT has had promising results; however, in terms of cost-effectiveness, the routine use of 11C- or 18F-choline PET/CT is still debatable. "
01/01/2023 - "Testicular metastasis of prostate origin diagnosed by PET/MR with 18F-Choline."
06/01/2022 - "In a retrospective study, 18F-choline PET/CT detected distant metastases in 27/58 high-risk nmCRPC patients with prior negative conventional imaging. "
12/01/2021 - "Skeletal Muscle Metastases in HCC Revealed by 18F-Choline PET/CT."
08/23/2021 - "Testicular metastasis of prostate origin diagnosed by PET/MR with 18F-Choline."

09/01/2018 - "18F-choline PET/MRI in suspected recurrence of prostate carcinoma."
04/01/2018 - "Virchow Node From Prostate Carcinoma by 18F-Choline PET/CT."
01/01/2018 - "Diagnostic performance of a streamlined 18F-choline PET-CT protocol for the detection of prostate carcinoma recurrence in combination with appropriate-use criteria."
09/01/2017 - "Incidental Papillary Bladder Carcinoma on 18F-Fluoromethylcholine PET/CT Undertaken to Evaluate Prostate Malignancy."
11/01/2016 - "Breast Cancer Incidentally Detected by 18F-Choline PET/CT in a Patient With Recurrent Prostate Carcinoma."

09/01/2021 - "The aim of this study was to evaluate the diagnostic performance of 18F-choline PET and MRI in patients with primary hyperparathyroidism. "
06/01/2023 - "Detection, resection and cure: a systematic review and meta-analysis of 18F-choline PET in primary hyperparathyroidism."
05/01/2022 - "Detectability of 18F-choline PET/MR in primary hyperparathyroidism."
09/01/2021 - "18F-choline PET/CT is clearly superior to MRI for localization diagnostics in primary hyperparathyroidism. "
09/01/2021 - "18F-Choline PET/CT, MRI, and Software-Based Image Fusion Analysis in Patients With Primary Hyperparathyroidism."